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Background: To establish the frequency of impulse control disorder (ICD) in Parkinson’s
disease (PD).
Methods: Within the Luxembourg Parkinson’s Study, PD patients were evaluated for
ICD presence (score ≥ 1 on MDS-UPDRS I item 1.6), use of dopamine agonists (DA)
and other medications.
Results: 470 patients were enrolled. Among 217 patients without DA use, 6.9% scored
positive for ICD, vs. 15.4% among 253 patients with DA use (p = 0.005). The regression
analysis showed that age at PD diagnosis had only a minor impact on ICD occurrence,
while there was no influence by gender or co-medications. The longitudinal study over 2
years in 156 patients demonstrated increasing ICD frequency in DA users (p = 0.005).
Conclusion: This large and non-interventional study confirms that PD patients with
DA treatment show higher frequency of ICD than patients without DA use. It newly
demonstrates that ICD can develop independently from age, gender, or co-medications.
Keywords: impulse control disorder, dopamine agonists, Parkinson’s disease (PD), risk factors, longitudinal
analysis
INTRODUCTION
Impulse control disorder (ICD) has been described by the World Health Organization (WHO)
in 1992 as “repeated acts that have no clear rational motivation, generally harm the person’s own
interests and those of other people, and are associated with impulses the person experiences as
uncontrollable” (1).
Following the WHO definition, four types of ICD have been defined: binge eating, excessive
shopping, pathological gambling and hypersexuality (2, 3). Pilot studies on ICD in PD have also
proposed to classify hobbyism and sometimes punding under the ICD umbrella (4, 5). Although
the latter behaviors may also reflect perturbed impulse-control, they are less strictly defined and are
frequently overlapping with normal behavior (6).
The dopamine dysregulation syndrome characterized by excessive and addictive use of
dopaminergic medication can be more easily dissected, as in contrast to ICD, it overwhelmingly
is due to excessive use of levodopa and not dopamine agonists (6, 7).
The frequency of ICD in de novo PD patients is similar to the general population (5), but
numerous studies reported higher frequency during the course of the disease (8–12). Treatment by
dopamine agonists (DA), mainly through stimulation of the D3- receptor (13) has been proposed
as a causal factor.
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However, there is ongoing debate on other risk factors, as
not every PD patient treated by DA develops ICD. Previous
studies essentially recruited younger PD patients or those with
a more rapid disease progression in tertiary care centers (5, 9,
11). Therefore, these studies cannot extrapolate their findings to
the general PD population. Potential further risk factors such
as age at PD diagnosis, gender, genetic susceptibility factors,
comorbidities, or co-medication have been poorly addressed
(14). Whether the dopamine agonist specifically or the dopamine
replacement therapy in general, reflected by the levodopa
equivalent daily dosis (LEDD), is implicated in the development
of ICD, is also subject of discussion. Finally, the development of
ICD in PD over time has only been explored in a few longitudinal
studies (5, 9, 11).
The present study could successfully circumvent some of
these reservations. The Luxembourg Parkinson’s study (15) was
designed to be as inclusive as possible by active recruitment of
also elderly participants or those with reduced mobility, thus best
representative of the general PD population (16). This allows our
study to produce statistically robust data on most of these so far
debatable issues.
METHODS
Cohorts of PD Patients and Controls
PD patients were recruited from the Luxembourg Parkinson’s
study (15). In this descriptive, longitudinal, prospective
study, participants benefit from detailed annual follow-up
examinations.” Subjects were eligible for the study when fulfilling
the following criteria: PD diagnosis based on the UK PD Society
Brain Bank criteria (17) and a score of ≥18 points on the
Montreal Cognitive Assessment (MoCA) (18) in order to ensure
sufficient comprehension of the questionnaires used. Patients
with atypical PD were excluded. Based on DA treatment, patients
were divided in two groups: “DA-users” (DA+) and “non DA-
users” (DA–). They were adjusted for age and gender. Controls
were also recruited from the Luxembourg Parkinson’s study (15).
They only had a baseline assessment and were adjusted for age at
study entry with patients classified as DA–. We excluded controls
with any suspicion of incident PD or under DA treatment for
other medical reasons. For the longitudinal analysis in PD
patients, we only considered those who did not secondarily
convert into atypical Parkinsonism.
Assessments
For each enrolled subject we assessed the demographic data and
the current medication, including levodopa, DA, amantadine
and antidepressants. Based on the indicated dosages of all
dopaminergic agents, a levodopa equivalent daily dose was
calculated (LEDD) (19). Previous dosages of the present
medication were not assessed. We evaluated the MDS-UPDRS
part I-IV (20) and the modified Hoehn and Yahr scale (21).
Similarly to another study on ICD occurrence in PD (5), ICD
was evaluated by assessing MDS-UPDRS part I item 1.6. This
Abbreviations: DA, dopamine agonist; DA+, DA-users; DA-, non DA-users;
ICD, impulse control disorder; LEDD, levodopa equivalent daily dosage; MDS-
UPDRS,Movement Disorder Society Unified Parkinson’s Disease Rating Scale; PD,
Parkinson’s disease; V1, Visit 1; V3, Visit 3.
item quantifies ICD with a score ranging from zero (normal) to
four (severe). We defined the presence of ICD by a score ≥ 1, as
previously proposed (5).
Of note, the proposed text of the MDS-UPDRS part I item
1.6 was explained in detail to the patient, with the examiner
insisting on the five above-mentioned symptoms of ICD. Any
allusion to punding as well as excessive and addictive intake of
the dopaminergic medication were disregarded.
Statistical Analyses
The study data weremanaged by using the Redcap electronic data
capture tools (22). The statistical analyses were performed using
SPSS Statistics version 25 and SAS V9.3 (SAS Institute, Cary, NC,
USA). All tests were two-sided and p ≤ 0.05 were considered
statistically significant. Assumption of normality was tested by
the Shapiro-Wilk test. ICD frequency was calculated by a chi
square test and demographic variables also by theMann-Whitney
U-test as adequate. We performed a logistic regression model to
estimate the relationship between ICD presence and confounding
factors by putting them all into one model. In a second analysis,
interactions between DA use and the annual visits V1 and V3
were tested. In both models, adjustments on gender and age
were implemented.
All patients had given written consent before entering the
Luxembourg Parkinson’s study (15). The study was approved
by the National Ethics Board (CNER Ref: 201407/13) and the
National Data Protection Committee (CNPD Ref: 446/2017).
RESULTS
Baseline Characteristics
BetweenMarch 2015 andDecember 2019, 470 patients (mean age
66.4 [39.4–86.4] years) and 429 controls (mean age 66.8 [55.2–
89.5] years) were eligible for the study. Two hundred and fifty
three patients (54%) were classified DA+ and 217 DA– (mean age
66.6 [51–86] vs. 66.9 years [39–80], p= 0.2). DA+ were younger
at PD diagnosis than DA– (58.5 [27.2–78.4] vs. 61.2 [31.3–79.4]
years; p = 0.001) and had a longer disease duration (8.1 [0–34]
vs. 5.7 [0–26] years, p < 0.001). The complete comparison of the
demographic data is shown in Table 1.
ICD Frequencies
Based on the answers to the assessment, ICD frequency was
higher in PD patients than in controls (11.5 % vs. 4.6%; p <
0.001). This difference was probably due to a higher positive
scoring in DA+ (39 out of 253 DA+ [15.4%] vs. 15 out of 217
DA- [6.9%], p= 0.005).
Fifty four patients in total scored positive for ICD (38 males
and 16 females). The most common ICD subtype in men was
binge eating and in women excessive shopping. The detailed data
about ICD subtypes and male-female distribution can be found
in Table 2.
Twenty one Patients with advanced treatment (19 with Deep
brain stimulation, two with apomorphine or Duodopa-pump)
were included. Three patients with DBS scored positive for ICD.
There was no statistically significant association between DBS
treatment and ICD symptoms (p= 0.55).
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TABLE 1 | Demographics and medication profile in 470 patients (253 DA+, 217 DA–) and 429 controls.
All PD patients PD DA+ PD DA- p-value
DA+ vs. DA–
Controls p-value
PD DA– vs. controls
Subjects 470 253 217 429
Demographics
Male sex (%) 308 (65.5%) 156 (61.7%) 152 (70.0%) 0.06 234 (54.5%) <0.001**
Years of education (yrs.) 13.0 (±3.9) 13.1 (±3.6) 12.9 (±4.3) 0.70 13.8 (3.7) 0.01*
MoCA 25.2 (±3.1) 25.4 (±3.0) 24.9 (±3.2) 0.11 26.9 (2.5) <0.001**
Age at baseline (yrs.) 66.8 (±8.5) 66.6 (±8.0) 66.9 (±9.0) 0.18 66.8 (8.5) 0.35
Age at PD onset (yrs.) 59.8 (±9.9) 58.5 (±9.3) 61.2 (±10.4) 0.001** n.a n.a
PD duration (yrs.) 6.9 (±5.5) 8.0 (±5.5) 5.7 (±5.2) <0.001** n.a n.a
LEDD (mg) 559 (±441) 696 (±429) 397 (±399) <0.001** 0 n.a
Scores
MDS-UPDRS I 1.6 = 0 (n) 416 (88.5%) 214 (84.6%) 202 (93.1%) n.a 409 (95.4%) n.a
MDS-UPDRS I 1.6 ≥ 1 (n) 54 (11.5%) 39 (15.4%) 15 (6.9%) n.a 20 (4.6%) n.a
MDS-UPDRS III (score) 33.2 (±14.4) 33.2 (±15.3) 33.2 (±13.3) 0.8 3.7 (4.0) n.a.
Hoehn & Yahr (score) 2.1 (±0.9) 2.2 (±0.7) 2.1 (±0.6) 0.61 0 n.a
Medication
Amantadine (n) 81 (17.2%) 48 (19.0%) 33 (15.2%) n.a n.a n.a
Antidepressants (n) 64 (13.9%) 34 (13.2%) 30 (14.4%) n.a 20 (4.6%) n.a
Ropinirole (n) 63 (13.4%) 63 (26.8%) 0 n.a 0 n.a
Pramipexole (n) 146 (31.1%) 146 (62.2%) 0 n.a 0 n.a
Rotigotine (n) 32 (6.8%) 32 (13.6%) 0 n.a 0 n.a
Apomorphine (n) 1 (0.6%) 1 (1.2%) 0 n.a 0 n.a
Piribedil (n) 16 (3.4%) 16 (6.8%) 0 n.a 0 n.a
p-values concern differences between DA+ and DA– (*p < 0.05, **p < 0.01). Some patients take >1 DA, which explains >100% in the DA+.
TABLE 2 | ICD subtypes with male-female distribution in subjects with






Binge eating (n) 12 2 p = 0.14
Excessive shopping (n) 7 4 p = 0.58
Pathological gambling (n) 0 2 p = 0.03*
Hypersexuality (n) 6 0 p = 0.09
Hobbying (n) 5 2 p = 0.95
Total (n) 30 10
*p ≤ 0.05 is considered statistically significant.
Notably, there was no significant difference in ICD frequency
between DA- patients and controls (6.9% vs. 4.6%, p= 0.21).
Potential ICD Risk Factors
We analyzed the potential influence of ICD risk factors by a
logistic regression model (Supplementary Table 1). We found
that younger age at disease onset independently affected ICD
occurrence (p = 0.03). We also found that the higher the age
of onset, the higher the ICD frequency. The odds ratio was
borderline significant (OR = 1.003, 95%CI= [1.000; 1.006]).
There was no influence of gender (p = 0.1), disease duration
(p = 0.2), UPDRS III (p = 0.06), use of amantadine (p = 0.5)
or antidepressants (p = 0.5). Despite the fact that LEDD was
higher in DA+ than in DA– (696 [0–1625] vs. 397mg [0–2112],
p < 0.001) our model did not show an association (p = 0.2).
In a next step, we adjusted both patient subgroups for age at
PD diagnosis: 242 DA+ and 203 DA–. The difference in ICD
frequency was maintained (14.9% vs. 7.4, p = 0.02). In a final
step, we separately analyzed ICD occurrence in 285 PD patients
older than 65 years at study entry: 145 DA+ and 140 DA–
patients. Here, the difference was also maintained (12.5% vs.
4.3%, p= 0.01).
Longitudinal Follow-Up of ICD
The database identified 193 patients having accomplished visits
V1 to V3. Three patients were excluded because of conversion
into atypical parkinsonism during follow-up (one patient was
reclassified as Lewy Body Dementia and two as secondary
parkinsonism). We based our analysis on the 156 patients with
unchanged DA group adherence from baseline to V3: 102 PD
patients in the DA+ subgroup and 54 patients in the DA-
subgroup. There was a sharp increase from baseline to V3 in
the DA+ subgroup (7.9% vs. 26.5%, p < 0.001). In contrast,
ICD frequency remained stable in the DA- group (5.6%). When
comparing ICD occurrence between both groups at V3, the
difference was again significant (26.5% vs. 5.6%, p < 0.001)
(Figure 1). Of note, we did have participants with a longer follow-
up period (up to 4 years). However, statistical robustness of
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FIGURE 1 | ICD evolution in PD patients (102 DA+, 54 DA–) with unchanged DA group adherence over time. DA+ in blue, DA– in orange. Increase of ICD in DA+
between baseline and V3. Difference between DA+ and DA– (**p < 0.01).
a longitudinal model was not achieved because of insufficient
subjects and these data are not shown.
DISCUSSION
This study confirms a higher ICD frequency in DA+ than in DA-
PD patients. As frequency in DA- is similar to the frequency in
age-adjusted controls, ICD is not a PD-inherent syndrome. Age
at PD onset is a significant co-factor, but age at study entry is not.
Remarkably, ICD frequency remains significantly higher in aged
PD patients treated by DA compared to those not treated by DA.
Our study argues against the initial concepts that ICD incidence
would increase with male gender, or higher motor deficits (9, 23).
It has been proposed that LEDD plays a role as a risk
factor, which is not supported by our data. In our cohort, the
total LEDD contains a substantially higher part of levodopa
than of DA. However, in contrast to DA, levodopa does not
preferentially stimulate the D3– receptor imputed in generation
of ICD symptoms by its impact on cognitive and emotional
functions (13). In addition, amantadine, prescribed in 17% of the
patients in this cohort, did not show any protective effect against
ICD occurrence (24, 25).
There has also been interest in a potential genetic
predisposition for ICD in PD. In one study, the dopamine
D3 receptor Ser9Gly variant has been linked to higher prevalence
of ICD (26). Two variants of the opioid receptor OPRM1
(rs17999 and rs702764) have been associated with decreased
odds of ICDs (27, 28). Mutations of the PINK1 and Parkin have
been identified as risk factors for ICD (29, 30). All these results
await confirmation in independent, larger cohorts.
In the longitudinal analysis, we observed a sharp increase of
ICD frequency in DA+ between baseline and V3. We have no
data on DA treatment duration and DA dosage before study
entry, so we cannot explicitly dissect if this increase is a time
or a dosage effect, reflecting DA accumulation over the years.
The latter seems more probable although there may exist an
individually variable “tipping point” in terms of postsynaptic
dopaminergic hypersensitization (13).
It is appealing to compare our data with other longitudinal
studies from Europe, althoughmost of them had a cross-sectional
design and were conducted in tertiary care centers. However,
studies with a longitudinal follow-up design remain rare. The
DIGPD study (France) (5) and the ICARUS study (Italy) (9) are
both large, multicenteric cohorts. The DIGPD study (5) included
411 patients (average follow-up 3.3 years); an increase of ICD
from 19.7% at baseline to 32.8% after 5 years was reported. With
1,069 subjects included, the ICARUS study (9) reported an ICD
prevalence of 26.8% after a 2 year follow-up.
In the U.S., the Prospective Cohort Study of Impulse Control
Disorders in Parkinson’s disease (11) longitudinally screened
164 subjects for ICD over 4 years. 39.1% of subjects with DA
treatment developed ICD after an average of 21 months. In
comparison to these studies, the frequency of ICD at baseline and
after 2 years in our study is rather low. This could be due to a
more cautious use of DA by the clinicians, based on their acquired
knowledge of risky ICD behavior and, in particular, to the more
restrictive definition of ICD in our study. However, the lower
frequency in the present study probably better reflects numbers
expected in the general PD population, but at the same alerts the
clinician of increasing frequency of ICD over time.
Several strengths of this study have to be outlined. First, the
recruitment of PD patients without any limitations imposed by
age or comorbidities allowed a broader appreciation of ICD in
the general PD population than in three other studies (5, 9, 11).
With a mean age of 65 years, PD patients in our study are also
substantially older than those studies (5, 9, 11) (mean age 58,
59 and 62 years, respectively). Second, the inclusive Luxembourg
Parkinson’s study (15) design also circumvented the preferential
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recruitment of patients in need of advanced treatment. Third,
the physicians in the present observational study were not
prescribing nor interfering with treatment. Finally, we were
able to follow a large and unselected subgroup of patients
longitudinally over three visits, as rarely done before and not at
this scale.
Our study has several limitations: first, comparably to other
studies (5, 11), ICD occurrence was not confirmed by a second
test and defined by MDS-UPDRS part I item 1.6.
In particular, we did not systematically use the Questionnaire
for Impulsive-Compulsive Disorders in Parkinson’s disease
(QUIP) (31), as it is subject to false positive findings. Due
to antidepressant use (12), it can produce up to 40% false
positive results due to an over-identification or an experience
of subsyndromal symptoms (32). Second, we have no reliable
data on the medication used before study entry. Finally, our
dataset did not allow comparing different DA release forms as
lower ICD frequencies have been reported with transdermal DA
treatment (33).
In conclusion, our study shows that in PD patients there is a
strong association between ICD occurrence and DA treatment.
It is independent from gender and age at study entry. Our
study cannot robustly show if there is a gender impact on the
ICD subtype.
ICD frequency substantially increases over time. Preliminary
results from visits 4 and 5 similarly show a trend for ascending
ICD frequency over time, but the data obtained so far are
insufficient for valid statistical interpretation.
Future research has to identify the type of DA application
at highest risk for ICD (34). Analyzing cognitive, affective and
motivational correlates or initial PD manifestations could be
of interest as well (35). Possibly, the most promising path will
be the identification of distinct genotypes that increase the risk
for ICD (29, 30). Physicians prescribing DA treatment have
to be attentive to the risk of these side effects in any PD
patient, independent from disease duration and age. They should
regularly re-interview PD patients on ICD occurrence, as early
ICD absence does not preclude later manifestation.
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